0000000001174803

AUTHOR

A Deshpande

showing 4 related works from this author

Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic

2021

Association of Surgeons in Training Surgical Summit, online, 17 Oct 2020 - 17 Oct 2020 2021 Virtual Annual Meeting / Surgical Research Society, online, 24 Mar 2021 - 25 Mar 2021, National Research Collaborative Meeting, online, 10 Dec 2020 - 10 Dec 2020, Royal Australasian College of Surgeons Annual Academic Surgery Conference, online, 5 Nov 2020 - 5 Nov 2020; The British journal of surgery : BJS 108(12), 1448-1464 (2021). doi:10.1093/bjs/znab336

MaleRespiration Artificial/statistics & numerical dataSettore MED/18 - CHIRURGIA GENERALEeducation-Sciences du Vivant [q-bio]/Médecine humaine et pathologieAbdominal NeoplasmPostoperative Complications/mortalityNOsurgeryCohort Studies03 medical and health sciencesCOVID-19; death; SARS-CoV-2; surgery0302 clinical medicinePostoperative ComplicationsdeathHumans030212 general & internal medicinePandemicsAbdominal Neoplasms/surgeryAgedLS7_4COVID-19/mortalityRespiratory Distress SyndromePandemicSARS-CoV-2Respirationsurgical procedures operativemortalitysurgery specialtypandemicspulmonary complicationssars-cov-2covid-19coronavirus pandemicCOVID-19Middle Aged3126 Surgery anesthesiology intensive care radiologyRespiration Artificialsurgical proceduresoperativemortalitysurgery specialtypandemicspulmonary complicationssars-cov-2covid-19coronavirus pandemicAbdominal Neoplasms; Aged; COVID-19; Cohort Studies; Female; Humans; Male; Middle Aged; Pandemics; Postoperative Complications; Respiration Artificial; Respiratory Distress Syndrome; Elective Surgical ProceduresElective Surgical Procedures030220 oncology & carcinogenesisAbdominal NeoplasmsArtificialFemalePostoperative ComplicationCohort Studie[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyRespiratory Distress Syndrome/mortalityHuman
researchProduct

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

2013

BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…

MESH: Pulmonary EmbolismMale[SDV]Life Sciences [q-bio]Kaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawMESH: Double-Blind Method030212 general & internal medicineMESH: WarfarinMESH: AgedMESH: Middle AgedHazard ratioGeneral MedicineVenous ThromboembolismMiddle AgedThrombosis3. Good healthPulmonary embolismAnesthesiaFemaleAnticoagulants EdoxabanMESH: HemorrhageAndexanet alfamedicine.drugMESH: EnoxaparinHemorrhageMESH: AnticoagulantsMESH: Drug Administration ScheduleDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodAged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; WarfarinmedicineHumansEnoxaparinAdverse effectMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryWarfarinAnticoagulantsmedicine.diseaseMESH: MalechemistryWarfarinbusinessPulmonary EmbolismMESH: FemaleNew England Journal of Medicine
researchProduct

Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000-2018

2021

Exclusive breastfeeding (EBF)—giving infants only breast-milk for the first 6 months of life—is a component of optimal breastfeeding practices effective in preventing child morbidity and mortality. EBF practices are known to vary by population and comparable subnational estimates of prevalence and progress across low- and middle-income countries (LMICs) are required for planning policy and interventions. Here we present a geospatial analysis of EBF prevalence estimates from 2000 to 2018 across 94 LMICs mapped to policy-relevant administrative units (for example, districts), quantify subnational inequalities and their changes over time, and estimate probabilities of meeting the World Health …

RJ101Psychological interventionBreastfeedingSocial SciencesgeographyBehavioral Neuroscience0302 clinical medicineRA0421PrevalencePsychologypolicy making030212 general & internal medicinePolicy Makinghumansmedia_commonCHILD GROWTH FAILUREDeveloping world0303 health scienceseducation.field_of_studyPsychology BiologicalGeographyPsychology ExperimentalHealth Status DisparitieMultidisciplinary SciencesGeographyBreast Feedingbreast feedingScale (social sciences)Science & Technology - Other TopicsLife Sciences & BiomedicineHumanAFRICASocial PsychologyInequalityspatial analysismedia_common.quotation_subjectpublic policyPopulationprevalencePublic policyDeveloping countryExperimental and Cognitive PsychologyPublic PolicyLocal Burden of Disease Exclusive Breastfeeding CollaboratorsArticleDeveloping Countrie03 medical and health sciencesEnvironmental healthHumansNutrition disorderseducationDeveloping Countries030304 developmental biologySpatial AnalysisScience & TechnologyNeurosciencesHealth Status Disparitiesdeveloping countrieshealth status disparitiesRisk factorsNeurosciences & NeurologyBreast feedingNature Human Behaviour
researchProduct

Mapping routine measles vaccination in low- and middle-income countries

2021

The safe, highly effective measles vaccine has been recommended globally since 1974, yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in children under 5 years old, and more than 99% of both occurred in low- and middle-income countries (LMICs)1–4. Globally comparable, annual, local estimates of routine first-dose measles-containing vaccine (MCV1) coverage are critical for understanding geographically precise immunity patterns, progress towards the targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions to vaccination programmes caused by coronavirus disease 2019 (COVID-19)5–8. Here we generated annual estimates of routine childhoo…

and promotion of well-beingVacunación MasivaInternationalityDisease preventionchildren under 5 years oldGeographic MappingRural Healthmedicine.disease_causeCross-reactivity0302 clinical medicineRA0421Vaccination Refusal030212 general & internal medicineChildimmunity patternsPediatric0303 health sciencesPublic healthMultidisciplinarybiologyVaccinationUncertaintyIMMUNIZATION3142 Public health care science environmental and occupational healthCOVERAGE3. Good healthTIME3.4 VaccinesChild PreschoolInfectious diseasesA990 Medicine and Dentistry not elsewhere classifiedAntibodyEngineering sciences. TechnologyAFRICAGeneral Science & TechnologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Disease prevention ; COVID-19 ; Public health ; Infectious diseases610 Medicine & healthGlobal Vaccine Action Plan (GVAP)Local Burden of Disease Vaccine Coverage CollaboratorsArticleVaccine Related03 medical and health sciencesmeasles vaccineMeasels ; Vaccination ; Low- and middle-income countries ; Local burden of disease ; Public healthClinical ResearchmedicineHumansHealthcare DisparitiesPreschoolPROGRESS030304 developmental biologybusiness.industryMORTALITYDeveloped CountriesPreventionCommentVacunaciónUrban HealthCOVID-19Prevention of disease and conditionsVirologyCoronavirusGood Health and Well BeingCobertura de Vacunaciónbiology.proteinImmunizationbusinessMeasles
researchProduct